Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07287189Phase 2Recruiting

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Role: lead

NCT06867107Phase 2Enrolling By Invitation

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

Role: lead

NCT06565208Early Phase 1Completed

First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort

Role: lead

All 3 trials loaded